daraxonrasib

DRUG8 trials

Conditions

Advanced Solid TumorsCRCColorectal CancerColorectal Cancer (CRC)Lung Cancer (NSCLC)Metastatic Pancreas AdenocarcinomaMetastatic Solid TumorsNSCLC

Phase 1

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

RecruitingNCT06128551

Revolution Medicines, Inc.Colorectal Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma

Start: 2023-11-14End: 2029-06-01Target: 534Updated: 2026-04-23

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

RecruitingNCT07349537

Revolution Medicines, Inc.Advanced Solid Tumors, Colorectal Cancer (CRC), CRC +7

Start: 2026-01-08End: 2028-10-01Target: 574Updated: 2026-02-04

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

RecruitingNCT07397338

Revolution Medicines, Inc.Advanced Solid Tumors, Colorectal Cancer (CRC), CRC +3

Start: 2026-01-30End: 2029-05-01Target: 370Updated: 2026-05-12

Phase 2

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not yet recruitingNCT07492680

Bristol-Myers SquibbSolid Tumors

Start: 2026-07-17End: 2032-05-20Target: 260Updated: 2026-03-25

Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

RecruitingNCT06881784

Revolution Medicines, Inc.Non-Small Cell Lung Cancer, NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) +2

Start: 2025-05-06End: 2030-12-01Target: 420Updated: 2026-03-12

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

RecruitingNCT07252232

Revolution Medicines, Inc.Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma +2

Start: 2025-12-15End: 2030-07-10Target: 500Updated: 2026-05-01

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

RecruitingNCT07491445

Revolution Medicines, Inc.Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenosquamous Carcinoma +5

Start: 2026-03-09End: 2029-03-01Target: 900Updated: 2026-05-14

Unknown Phase

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

NCT07573215

Revolution Medicines, Inc.Metastatic Pancreas Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic +5

Updated: 2026-05-07

Related Papers

Abstract CT215: RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC

Cancer Research2026-04-17

Abstract B046: Pan-RAS Inhibition as a novel therapeutic strategy for RAS-driven rhabdomyosarcoma

Cancer Research2026-03-05

Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers

Journal of Medicinal Chemistry2025-03-0832 citations

Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers

Journal of Medicinal Chemistry2025-02-2422 citations